Logo image of APDN

APPLIED DNA SCIENCES INC (APDN) Stock Fundamental Analysis

NASDAQ:APDN - Nasdaq - US03815U5083 - Common Stock - Currency: USD

4.56  -0.59 (-11.46%)

After market: 4.5 -0.06 (-1.32%)

Fundamental Rating

3

APDN gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 55 industry peers in the Life Sciences Tools & Services industry. While APDN seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, APDN is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

APDN had negative earnings in the past year.
APDN had a negative operating cash flow in the past year.
In the past 5 years APDN always reported negative net income.
In the past 5 years APDN always reported negative operating cash flow.
APDN Yearly Net Income VS EBIT VS OCF VS FCFAPDN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

APDN's Return On Assets of -354.31% is on the low side compared to the rest of the industry. APDN is outperformed by 98.18% of its industry peers.
APDN has a Return On Equity of -441.56%. This is amonst the worse of the industry: APDN underperforms 89.09% of its industry peers.
Industry RankSector Rank
ROA -354.31%
ROE -441.56%
ROIC N/A
ROA(3y)-55.66%
ROA(5y)-76.19%
ROE(3y)-114.94%
ROE(5y)-140.25%
ROIC(3y)N/A
ROIC(5y)N/A
APDN Yearly ROA, ROE, ROICAPDN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K -1K -1.5K

1.3 Margins

APDN has a Gross Margin (40.76%) which is comparable to the rest of the industry.
APDN's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for APDN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 40.76%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-18.42%
GM growth 5Y-18.75%
APDN Yearly Profit, Operating, Gross MarginsAPDN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

More info and screens

6

2. Health

2.1 Basic Checks

APDN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for APDN has been increased compared to 1 year ago.
Compared to 5 years ago, APDN has more shares outstanding
APDN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
APDN Yearly Shares OutstandingAPDN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2K 4K 6K 8K 10K
APDN Yearly Total Debt VS Total AssetsAPDN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

APDN has an Altman-Z score of -32.68. This is a bad value and indicates that APDN is not financially healthy and even has some risk of bankruptcy.
APDN has a Altman-Z score of -32.68. This is amonst the worse of the industry: APDN underperforms 98.18% of its industry peers.
There is no outstanding debt for APDN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -32.68
ROIC/WACCN/A
WACC10.11%
APDN Yearly LT Debt VS Equity VS FCFAPDN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M -10M -15M

2.3 Liquidity

A Current Ratio of 4.45 indicates that APDN has no problem at all paying its short term obligations.
The Current ratio of APDN (4.45) is better than 65.45% of its industry peers.
APDN has a Quick Ratio of 4.27. This indicates that APDN is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 4.27, APDN is in the better half of the industry, outperforming 69.09% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.45
Quick Ratio 4.27
APDN Yearly Current Assets VS Current LiabilitesAPDN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 95.81% over the past year.
The Revenue for APDN has decreased by -31.30% in the past year. This is quite bad
APDN shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -8.63% yearly.
EPS 1Y (TTM)95.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%94.22%
Revenue 1Y (TTM)-31.3%
Revenue growth 3Y-27.56%
Revenue growth 5Y-8.63%
Sales Q2Q%5.78%

3.2 Future

The Earnings Per Share is expected to grow by 40.85% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 45.04% on average over the next years. This is a very strong growth
EPS Next Y92.97%
EPS Next 2Y40.85%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year50.26%
Revenue Next 2Y45.04%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
APDN Yearly Revenue VS EstimatesAPDN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 5M 10M 15M
APDN Yearly EPS VS EstimatesAPDN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -100K -200K -300K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

APDN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for APDN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
APDN Price Earnings VS Forward Price EarningsAPDN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
APDN Per share dataAPDN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -100 -200 -300 -400 -500

4.3 Compensation for Growth

A more expensive valuation may be justified as APDN's earnings are expected to grow with 40.85% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.85%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

APDN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

APPLIED DNA SCIENCES INC

NASDAQ:APDN (7/1/2025, 7:21:03 PM)

After market: 4.5 -0.06 (-1.32%)

4.56

-0.59 (-11.46%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)05-15 2025-05-15/amc
Earnings (Next)08-06 2025-08-06
Inst Owners4.12%
Inst Owner Change-77.72%
Ins Owners0.99%
Ins Owner Change0%
Market Cap29.64M
Analysts43.33
Price TargetN/A
Short Float %N/A
Short Ratio0.16
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-235.28%
Min EPS beat(2)-401.63%
Max EPS beat(2)-68.93%
EPS beat(4)2
Avg EPS beat(4)-57.8%
Min EPS beat(4)-401.63%
Max EPS beat(4)231.65%
EPS beat(8)5
Avg EPS beat(8)-20.97%
EPS beat(12)8
Avg EPS beat(12)9.64%
EPS beat(16)9
Avg EPS beat(16)-7.06%
Revenue beat(2)1
Avg Revenue beat(2)-2.78%
Min Revenue beat(2)-18.66%
Max Revenue beat(2)13.1%
Revenue beat(4)1
Avg Revenue beat(4)-11.12%
Min Revenue beat(4)-27.61%
Max Revenue beat(4)13.1%
Revenue beat(8)3
Avg Revenue beat(8)-9.56%
Revenue beat(12)6
Avg Revenue beat(12)-3.83%
Revenue beat(16)9
Avg Revenue beat(16)-1.71%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-1400%
EPS NQ rev (3m)-1400%
EPS NY rev (1m)-1400%
EPS NY rev (3m)-1400%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)21.7%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.82
P/FCF N/A
P/OCF N/A
P/B 2.83
P/tB 3.82
EV/EBITDA N/A
EPS(TTM)-537.75
EYN/A
EPS(NY)-84.15
Fwd EYN/A
FCF(TTM)-2.15
FCFYN/A
OCF(TTM)-2.04
OCFYN/A
SpS0.58
BVpS1.61
TBVpS1.19
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -354.31%
ROE -441.56%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 40.76%
FCFM N/A
ROA(3y)-55.66%
ROA(5y)-76.19%
ROE(3y)-114.94%
ROE(5y)-140.25%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-18.42%
GM growth 5Y-18.75%
F-Score4
Asset Turnover0.29
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 179.02%
Cap/Sales 18.34%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.45
Quick Ratio 4.27
Altman-Z -32.68
F-Score4
WACC10.11%
ROIC/WACCN/A
Cap/Depr(3y)60.08%
Cap/Depr(5y)170.88%
Cap/Sales(3y)7.71%
Cap/Sales(5y)21.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)95.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%94.22%
EPS Next Y92.97%
EPS Next 2Y40.85%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-31.3%
Revenue growth 3Y-27.56%
Revenue growth 5Y-8.63%
Sales Q2Q%5.78%
Revenue Next Year50.26%
Revenue Next 2Y45.04%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y9.65%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-84.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-84.57%
OCF growth 3YN/A
OCF growth 5YN/A